Hormonal
Survodutide, a dual glucagon/GLP-1 receptor agonist, produces dose-dependent reductions in HbA1c and bodyweight in people with type 2 diabetes, with doses ≥1.8 mg once weekly yielding greater bodyweight loss than semaglutide 1.0 mg.
For individuals with type 2 diabetes seeking significant weight loss and glucose control, dual GLP-1/GCGR agonists like survodutide offer superior bodyweight reduction compared to standard GLP-1 therapies like semaglutide, particularly at doses of 1.8 mg/week or higher. Expect gastrointestinal side effects, which can be managed by starting with lower doses and escalating slowly.
Survodutide reduced HbA1c levels and bodyweight after 16 weeks’ treatment in participants with type 2 diabetes. ... survodutide ≥1.8 mg qw produced greater bodyweight reductions than semaglutide (−5.3% [−6.6, −4.1]; n=45).
Why this rating
Phase II randomized controlled trial with a large sample size (n=413) and rigorous statistical analysis (MMRM).
Source
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher et al. · Diabetologia · 2023
DOI 10.1007/s00125-023-06053-9
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →